Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination

Genetic diseases are often caused by nonsense mutations, but only one TRID (translation readthrough inducing drug), ataluren, has been approved for clinical use. Ataluren inhibits release factor complex (RFC) termination activity, while not affecting productive binding of near-cognate ternary comple...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shijie, Bhattacharya, Arpan, Ghelfi, Mikel D., Li, Hong, Fritsch, Clark, Chenoweth, David M., Goldman, Yale E., Cooperman, Barry S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076611/
https://www.ncbi.nlm.nih.gov/pubmed/35523781
http://dx.doi.org/10.1038/s41467-022-30080-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076611/
https://www.ncbi.nlm.nih.gov/pubmed/35523781
http://dx.doi.org/10.1038/s41467-022-30080-6

Ejemplares similares